Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1237-1248

  Macias, William L ^a   Bergstrom, Richard F ^a   Cerimele, Benito J ^a   Kassahun, Kelem ^a   Tatum, David E ^a   Callaghan, John T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLURIC ACID; 1,3 DIMETHYLURIC ACID; 3 METHYLXANTHINE; AMINOPHYLLINE; CIMETIDINE; GLUCURONIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENACETIN O DEETHYLASE; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STEADY STATE;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BENZODIAZEPINES; BRONCHODILATOR AGENTS; CIMETIDINE; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PIRENZEPINE; THEOPHYLLINE; URIC ACID; XANTHINES;

EID: 0031757721     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2(4):281-93.
2. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
3. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton SH. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
4. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
5. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154: 457-65.
6. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25(1):81-93..
7. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276(2):658-66.
8. Jenne JW, Nagasawa HT, Thompson RD. Relationship of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther 1976;19(3):375-81.
9. Sarkar MA, Jackson BJ. Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 1994;22(6):827-34.
10. Tang-Liu DD, Williams RL, Riegelman S. Nonlinear theophylline elimination. Clin Pharmacol Ther 1982; 31(3):358-69.
11. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr 1995;688:85-90.
12. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57:12-25.
13. Vestal RE, Cusack BJ, Mercer GD, Dawson GW, Park BK. Aging and drug interactions. I. Effect of cimetidine and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1987;241(2):488-500.
14. Anderson KE, McCleery RB, Vessell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 1991;13(5):941-6.
15. McEwen J, McMurdo ME, Moreland TA. The effects of once-daily dosing with ranitidine and cimetidine on theophylline pharmacokinetics. Eur J Drug Metab Pharmacokinet 1988; 13(3):201-5.
16. Bachmann K, Sullivan TJ, Mauro LS, Martin M, Jauregui L. Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients. J Clin Pharmacol 1992; 32(5):476-82.
17. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16(4):368-74.
18. Mäenpää J, Wrighton S, Bergstrom R, et al. Pharmacokinetic and pharmacodynamic interactions between fluvoxamine and olanzapine [abstr]. Clin Pharmacol Ther 1997;61(2):225.